Do you suffer from a headache or a migraine?
While only your doctor can provide a proper diagnosis and suggest
a treatment, there are some important distinctions between
migraines and headaches.
Migraines:
Headaches:
Pain is moderate to severe and can be strong enough
to interfere with daily activities
Pain tends to feel stabbing/throbbing and is usually
located in one part of the head
Pain lasts from 4 – 72 hours
Pain is often accompanied by secondary symptoms,
such as:
Sensitivity to light, sound,
or motion
Nausea
Vomiting
Pain does not respond well to over-the-counter treatments
like aspirin or ibuprofen
Pain is mild to moderate
Pain is all over the head
Pain is short lived
There are no secondary symptoms (such as vomiting,
auras, or sensitivity to motion)
Pain responds well to over –the–counter
treatments like aspirin or ibuprofen
If you think you may suffer from migraines, Talk
to Your Doctor today about your symptoms so
that you can get the relief you deserve.
IMPORTANT SAFETY INFORMATION:
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
Migranal Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. Migranal also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. Migranal Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Migranal Nasal Spray should not be administered to pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with Migranal Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for Migranal Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
